Effects of an antiulcer drug, sucralfate (a basic aluminum salt of sulfated disaccharide), on experimental gastric lesions and gastric secretion in rats.
The effects of oral sucralfate, a basic aluminum salt of sulfated disaccharide, on various experimental gastric lesions and on gastric secretion were studied in rats. Sucralfate at 300 mg/kg potently inhibited the development of Shay ulcers and indomethacin- and aspirin-induced erosions. The drug at 1000 mg/kg also potently inhibited histamine-induced erosions. Water-immersion stress-induced erosions were inhibited with 1000 mg/kg of the drug, but the degree of inhibition was weaker than that seen in other types of erosion formation. Sucralfate at 1000 mg/kg given twice daily for 14 days significantly accelerated the spontaneous healing of acetic acid-induced ulcers. Sucralfate at over 300 mg/kg tended to increase the volume of gastric juice but had an insignificant effect on acid and pepsin output of pylorus-ligated rats. As a whole, the effects of sucralfate on experimental gastric lesions appear to be much more potent than Maalox, propantheline bromide, and cimetidine. The mechanism of action of sucralfate remains to be determined.
D000085:Acetates; D000535:Aluminum / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001241:Aspirin; D005753:Gastric Mucosa / Q000378:metabolism; D006632:Histamine; D007213:Indomethacin; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced / Q000188:drug therapy*; D013392:Sucralfate
D000085:Acetates; D000897:Anti-Ulcer Agents; D013392:Sucralfate; D006632:Histamine; D000535:Aluminum; D001241:Aspirin; D007213:Indomethacin